High Body Mass Index May Predict Survival Outcomes in Renal Cell Carcinoma

Share this content:
Researchers assessed the outcomes of 2092 patients with nm-cRCC who received surgery with curative intent.
Researchers assessed the outcomes of 2092 patients with nm-cRCC who received surgery with curative intent.

High body mass index (BMI) may be prognostic of improved recurrence-free survival (RFS) and cancer-specific survival (CSS) among older patients with nonmetastatic clear cell renal cell carcinoma (nm-cRCC), according to findings published in the Journal of Surgical Oncology.1

Obesity is a known risk factor in the development of RCC and is present in more than a quarter of reported cases — but  its utility as a prognostic factor remains unclear. Furthermore, evidence for how obesity modifies mortality has been mixed once factoring in the age of the patient.

In the retrospective study, researchers assessed the outcomes of 2092 patients with nm-cRCC who received surgery with curative intent. Patients were categorized as young if they were younger than 45 years, and the mean BMI was 24.7±3.1 (there was no significant difference in BMI observed between the older and younger patient populations). Postoperative follow-ups were performed every 3 months for the first 6 months, every 6 months for the following 3 years, then every year thereafter. The median follow-up was 40 months. 

Results showed that BMI was an independent prognostic factor of RFS; the 5-year RFS rate was 89.1% among older patients with high BMI (>25 kg/m2) versus 84.3% among older patients with normal BMI (P< .003). Even after multivariate analysis, high BMI remained a significant predictor of RFS. Younger patients had 5-year RFS rates of 93.5% and 92.5% among the high BMI and low BMI groups, respectively (P= .457).

The 5-year CSS among older patients was 95.2% and 91.7% in high-BMI and low-BMI patients, respectively (P= .004); after taking into consideration confounding factors, high BMI was found to be an independent predictor for CSS in older patients. Among younger patients, the 5-year CSS was 98.0% in the high-BMI group and 96.6% in the normal-BMI group (P= .420). 

Findings of the study demonstrated that high BMI had prognostic value for RFS and CSS for patients with nm-cRCC, but only among older patients. The authors concluded that “there is an age-dependent relationship between obesity and nm-cRCC prognosis.”

References

  1. Byun SS, Hwang EC, Kang SH, et al. Age-dependent prognostic value of body mass index for nonmetastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis[published online June 27, 2018]. J Surg Oncol. doi: 10.1002/jso.25104

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs